Biotechnology R
Bayesian Design and Analysis (Clinical Regulatory Perspective) Celia Witten, Ph.D., M.D. Office Director, OCTGT, CBER, FDA FDA/ASA/Industry Statistics.
1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Third Annual HD Clinical Research.
